preventive effect for reinfection of human papillomavirus (HPV) 16/18 against cervical intraepithelial neoplasia (CIN) 1

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005656

Enrollment

200

Registered

2011-06-30

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient with cervical intraepithelial neoplasia (CIN) 1

Interventions

HPV typing test and receive Cervarix HPV typing test and not-receive Cervarix

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Sex: female 2.Age: and above 20, under 40 3.patients who have a diagnosis of low-grade squamous intraepithelial lesion (CIN 1) by tissue diagnosis

Exclusion criteria

Exclusion criteria: 1.obvious progression of squamous intraepithelial lesion 2.diagnosis of cervical cancer in past times 3.diagnosis of above middle-grade squamous intraepithelial lesion in past times 4.obvious fever 5.obvious any severe acute disease 6.history of hypersensitivity to any ingredient of Cervarix 7.during pregnancy 8.during lactation 9.receive live vaccine within 27 days 10.receive inactivated vaccine within 6 days

Design outcomes

Primary

Measure	Time frame
situation of infection with or without HPV 16/18 situation in one/ two year of both group	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026